379 related articles for article (PubMed ID: 34653515)
21. Food allergy immunotherapy: Oral immunotherapy and epicutaneous immunotherapy.
Kim EH; Burks AW
Allergy; 2020 Jun; 75(6):1337-1346. PubMed ID: 32034781
[TBL] [Abstract][Full Text] [Related]
22. Food-allergic infants have impaired regulatory T-cell responses following in vivo allergen exposure.
Dang TD; Allen KJ; J Martino D; Koplin JJ; Licciardi PV; Tang ML
Pediatr Allergy Immunol; 2016 Feb; 27(1):35-43. PubMed ID: 26456457
[TBL] [Abstract][Full Text] [Related]
23. Mucosal Nanoemulsion Allergy Vaccine Suppresses Alarmin Expression and Induces Bystander Suppression of Reactivity to Multiple Food Allergens.
Farazuddin M; Landers JJ; Janczak KW; Lindsey HK; Finkelman FD; Baker JR; O'Konek JJ
Front Immunol; 2021; 12():599296. PubMed ID: 33717078
[TBL] [Abstract][Full Text] [Related]
24. Analysis of cytokine production by peanut-reactive T cells identifies residual Th2 effectors in highly allergic children who received peanut oral immunotherapy.
Wisniewski JA; Commins SP; Agrawal R; Hulse KE; Yu MD; Cronin J; Heymann PW; Pomes A; Platts-Mills TA; Workman L; Woodfolk JA
Clin Exp Allergy; 2015 Jul; 45(7):1201-13. PubMed ID: 25823600
[TBL] [Abstract][Full Text] [Related]
25. Improvements in Quality of Life in Children Following Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in the PEPITES and PEOPLE Studies.
DunnGalvin A; Fleischer DM; Campbell DE; O'B Hourihane J; Green TD; Sampson HA; Greenhawt M
J Allergy Clin Immunol Pract; 2021 Jan; 9(1):216-224.e1. PubMed ID: 32841748
[TBL] [Abstract][Full Text] [Related]
26. Study protocol of a phase 2, dual-centre, randomised, controlled trial evaluating the effectiveness of probiotic and egg oral immunotherapy at inducing desensitisation or sustained unresponsiveness (remission) in participants with egg allergy compared with placebo (Probiotic Egg Allergen Oral Immunotherapy for Treatment of Egg Allergy: PEAT study).
Loke P; Chebar Lozinsky A; Orsini F; Wong LS; Leung AS; Tham EH; Lopata AL; Shek LP; Tang ML;
BMJ Open; 2021 Jul; 11(7):e044331. PubMed ID: 34233966
[TBL] [Abstract][Full Text] [Related]
27. Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy.
Patil SU; Steinbrecher J; Calatroni A; Smith N; Ma A; Ruiter B; Virkud Y; Schneider M; Shreffler WG
J Allergy Clin Immunol; 2019 Nov; 144(5):1310-1319.e4. PubMed ID: 31377342
[TBL] [Abstract][Full Text] [Related]
28. Epicutaneous immunotherapy for treatment of peanut allergy: Follow-up from the Consortium for Food Allergy Research.
Scurlock AM; Burks AW; Sicherer SH; Leung DYM; Kim EH; Henning AK; Dawson P; Lindblad RW; Berin MC; Cho CB; Davidson WF; Plaut M; Sampson HA; Wood RA; Jones SM;
J Allergy Clin Immunol; 2021 Mar; 147(3):992-1003.e5. PubMed ID: 33290772
[TBL] [Abstract][Full Text] [Related]
29. AR101 Oral Immunotherapy for Peanut Allergy.
; Vickery BP; Vereda A; Casale TB; Beyer K; du Toit G; Hourihane JO; Jones SM; Shreffler WG; Marcantonio A; Zawadzki R; Sher L; Carr WW; Fineman S; Greos L; Rachid R; Ibáñez MD; Tilles S; Assa’ad AH; Nilsson C; Rupp N; Welch MJ; Sussman G; Chinthrajah S; Blumchen K; Sher E; Spergel JM; Leickly FE; Zielen S; Wang J; Sanders GM; Wood RA; Cheema A; Bindslev-Jensen C; Leonard S; Kachru R; Johnston DT; Hampel FC; Kim EH; Anagnostou A; Pongracic JA; Ben-Shoshan M; Sharma HP; Stillerman A; Windom HH; Yang WH; Muraro A; Zubeldia JM; Sharma V; Dorsey MJ; Chong HJ; Ohayon J; Bird JA; Carr TF; Siri D; Fernández-Rivas M; Jeong DK; Fleischer DM; Lieberman JA; Dubois AEJ; Tsoumani M; Ciaccio CE; Portnoy JM; Mansfield LE; Fritz SB; Lanser BJ; Matz J; Oude Elberink HNG; Varshney P; Dilly SG; Adelman DC; Burks AW
N Engl J Med; 2018 Nov; 379(21):1991-2001. PubMed ID: 30449234
[TBL] [Abstract][Full Text] [Related]
30. Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy.
Fernandez-Rivas M; Vereda A; Vickery BP; Sharma V; Nilsson C; Muraro A; Hourihane JO; DunnGalvin A; du Toit G; Blumchen K; Beyer K; Smith A; Ryan R; Adelman DC; Jones SM
Allergy; 2022 Mar; 77(3):991-1003. PubMed ID: 34320250
[TBL] [Abstract][Full Text] [Related]
31. Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy.
Voskamp AL; Khosa S; Phan T; DeBerg HA; Bingham J; Hew M; Smith W; Abramovitch J; Rolland JM; Moyle M; Nadeau KC; Lack G; Larché M; Wambre E; O'Hehir RE; Hickey P; Prickett SR
Allergy; 2024 Feb; 79(2):485-498. PubMed ID: 38112286
[TBL] [Abstract][Full Text] [Related]
32. Dose and route of administration determine the efficacy of prophylactic immunotherapy for peanut allergy in a Brown Norway rat model.
Sztuk TKS; Rigby NM; Nørskov-Nielsen L; Koppelman SJ; Sancho AI; Knudsen NH; Marsh J; Johnson P; Gupta S; Mackie AR; Larsen JM; Bøgh KL
Front Immunol; 2023; 14():1121497. PubMed ID: 36911669
[TBL] [Abstract][Full Text] [Related]
33. Oral Immunotherapy: An Overview.
Todoric K; Merrill S
Prim Care; 2023 Jun; 50(2):269-281. PubMed ID: 37105606
[TBL] [Abstract][Full Text] [Related]
34. Egg-specific IgE and basophil activation but not egg-specific T-cell counts correlate with phenotypes of clinical egg allergy.
Berin MC; Grishin A; Masilamani M; Leung DYM; Sicherer SH; Jones SM; Burks AW; Henning AK; Dawson P; Grabowska J; Agashe C; Davidson WF; Wood RA; Sampson HA
J Allergy Clin Immunol; 2018 Jul; 142(1):149-158.e8. PubMed ID: 29518422
[TBL] [Abstract][Full Text] [Related]
35. Current Trend in Immunotherapy for Peanut Allergy.
Joo Chan C; Richardo T; Lim RLH
Int Rev Immunol; 2018; 37(6):279-290. PubMed ID: 30638084
[TBL] [Abstract][Full Text] [Related]
36. Thresholds of clinical reactivity to milk, egg, peanut and sesame in immunoglobulin E-dependent allergies: evaluation by double-blind or single-blind placebo-controlled oral challenges.
Morisset M; Moneret-Vautrin DA; Kanny G; Guénard L; Beaudouin E; Flabbée J; Hatahet R
Clin Exp Allergy; 2003 Aug; 33(8):1046-51. PubMed ID: 12911777
[TBL] [Abstract][Full Text] [Related]
37. Emerging Therapies for Peanut Allergy.
Hong TS; Hu A; Fahim G; Hermes-DeSantis ER
J Pharm Pract; 2022 Apr; 35(2):289-297. PubMed ID: 33148108
[TBL] [Abstract][Full Text] [Related]
38. Clinical efficacy and immune regulation with peanut oral immunotherapy.
Jones SM; Pons L; Roberts JL; Scurlock AM; Perry TT; Kulis M; Shreffler WG; Steele P; Henry KA; Adair M; Francis JM; Durham S; Vickery BP; Zhong X; Burks AW
J Allergy Clin Immunol; 2009 Aug; 124(2):292-300, 300.e1-97. PubMed ID: 19577283
[TBL] [Abstract][Full Text] [Related]
39. The impact of a baked muffin matrix on the bioaccessibility and IgE reactivity of egg and peanut allergens.
Mattar H; Padfield P; Simpson A; Mills ENC
Food Chem; 2021 Nov; 362():129879. PubMed ID: 34118511
[TBL] [Abstract][Full Text] [Related]
40. Administration of a probiotic with peanut oral immunotherapy: A randomized trial.
Tang ML; Ponsonby AL; Orsini F; Tey D; Robinson M; Su EL; Licciardi P; Burks W; Donath S
J Allergy Clin Immunol; 2015 Mar; 135(3):737-44.e8. PubMed ID: 25592987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
